What is taking so long to launch our new meds?

FDA OKs Umeclidinium (Incruse Ellipta) for COPD
April 30, 2014

The US Food and Drug Administration (FDA) has approved umeclidinium (Incruse Ellipta, GlaxoSmithKline) as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, according to the company.

Are we the only company in Pharma that sits on a new approval for 6-9 months before launching?

 

What! You don't thnk GSK wanted to launch it during the upcoming fall respiratory season since when it launches miserably they can always claim it was due by the time it took to get stocked its springtime and physicians just aren't switching to new products. What a POS company